Imperial College London





INVESTIGATOR SITE HEADED PAPER

Sepsis Trials in Critical Care - SepTiC Retrospective Information Summary and Consent form

You are being invited to continue to participate in our research study. Sepsis is when the body overreacts to an infection and starts to damage itself. This study is trying to find the best treatments for sepsis. This form provides summary information on the study, the treatments we are using, what has happened and what will happen if you decide to continue as well as the risks and benefits of taking part.

Please take time to read the following information carefully and do talk about it with other people if you would like to. Ask us if there is anything that you do not understand or if you would like more information. You can take time to think about whether you wish to continue taking part in the study.

What are the treatments?

We are testing three different treatments in this study: -

- 1. Diagnostic Trial this involves a PCR test that quickly tells us what bacteria may be causing the infection and may help us decide which antibiotics to give.
- 2. Fluid Trial giving fluid is routine when treating sepsis, but there is no clear guide on how best to provide the treatment, so we will test how much fluid should be given and if medication should be given to remove any build-up of extra fluid.
- 3. GM-CSF Trial this drug can help the immune system fight infection by making more white blood cells.

These treatment options listed above also include a 'standard care' or 'placebo' option. A computer randomly selects which treatment options you have received. This means you might not have received any of these treatments, even if you choose to continue to participate in the SepTiC trial. How patients recover over time is then compared between the different treatment options to work out which treatments are best.

What do I need to do?

Treating sepsis quickly is important and therefore you were included in the trial when you were very unwell and lacked the capacity to discuss the study. We have spoken to a relative / friend or an independent doctor about your taking part. You may already have received treatment and a few extra blood samples may have been collected.

You do not need to do anything for the study while you are in hospital. We will collect data from your hospital records and other NHS linked data. We may contact you 3 months later to see how you are and would like to contact you 6 months later with a short telephone call to ask about your quality of life, and wellbeing.

Participation into the SepTiC trial is voluntary. All patients, including those that do not wish to participate in SepTiC, will receive the best available standard of care available at this hospital. You can choose not to take part in the study any more.

More information about the study including how we use patient data and privacy, legalities and insurance of the study, risks and benefits, how to make a complaint and how to find out the results of the study can be found in our patient information sheet. (A written copy is available or is available online at www.septictrial.co.uk)

Protocol Number: 22SM8039

Page 1 of 3

If you are happy to proceed, please complete the attached consent form.

Site Contact Information

Investigator name:-Site Contact details:-

Study Contact Information

Please contact The **SepTiC** Trial team using the following contact details:

Name: The **SepTiC** Trial Team 24hr Telephone: 0207 5949725 Email: septic@imperial.ac.uk Website: www.septictrial.co.uk

Thank you very much for continuing to take part in this study!

A copy of the written information and signed Informed Consent form will be given to you to keep.

Consent Form for Participants – Regained capacity

Full Title of Project: Sepsis Trials in Critical Care - SepTiC

| Site n | umber: | | |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|--------------------|
| Patient Number: | | | |
| Patien | t Name: | | |
| Name | of Principal Investigator: | | |
| | | | Please initial box |
| 1. | I confirm that I have read and understand copy of the appropriate patient information | • | |
| 2. | I confirm I am happy to consent to continu Diagnostic and Fluid Trial GM-CSF Trial. | ue to participate in the following trials: | |
| 3. | I confirm that I understand the SepTiC stuquestions which have been answered fully | · · · · · · · · · · · · · · · · · · · | |
| 4. | I understand that my participation is voluntary, and I am free to withdraw at any time, without giving any reason and without my legal rights nor treatment / healthcare being affected. | | |
| 5. | I understand that sections of any of my m responsible individuals from Imperial Colle regulatory authorities where it is relevant | ege London, from the NHS Trust or from | |

SepTiC Retro_Sum ORIG V1.0 22.08.2023

IRAS ID 1005848

Protocol Number: 22SM8039

Page 2 of 3

| research or in the academic instituti | nformation collected about me to be used development of a new test, medication, or on or commercial company in the future, ir dom (which Imperial has ensured will keep | r treatment by an nocluding those outside | | | |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|--|--|--|
| other research or academic instituti | samples (human tissue) collected about me in the development of a new test, medicat on or commercial company in the future, ir dom (which Imperial has ensured will keep | ion, or treatment by an ncluding those outside | | | |
| to Imperial College | tissue samples and / or data collected from e and that I will not personally benefit final on and/or the successful development of a ct or service. | ncially if this research | | | |
| 9. I give consent to b studies. | | | | | |
| data collection an | the use of data already collected in the triad follow up information to be obtained from 12 months after my inclusion | | | | |
| may be examined people working or | 11. I agree that my medical records and other personal data generated during the study may be examined by representatives of the sponsor (Imperial College London), by people working on behalf of the sponsor, and by representatives of Regulatory authorities, ICNARC, NHS Digital and SICSAG where it is relevant to my taking part in this research. | | | | |
| | e samples being used to undertake genetion to generate data that can be tracked back | - | | | |
| 13. I consent to contin | nue to take part in SepTiC | | | | |
| | | • | | | |
| Name of patient | Signature | Date | | | |
| Name of staff member (Listed on delegation log) | Signature | Date | | | |

1 copy for participant; 1 copy for Principal Investigator 1 copy for hospital notes

To ensure confidence in the process and minimise risk of loss, all consent forms <u>must</u> be printed, presented, and stored in double sided format

Protocol Number: 22SM8039